Sino Biopharmaceutical gets approval for COPD drug trial
Sino Biopharmaceutical Limited announced that its independently developed drug, TQC3302, has received clinical trial approval from China's National Medical Products Administration.
The triple-combination formulation uses the company's soft mist inhalation technology platform for maintenance treatment of chronic obstructive pulmonary disease.
The company noted that no similar triple-combination soft mist inhalation formulation is currently approved for global marketing, positioning TQC3302 to offer additional treatment options for COPD patients.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Sino Biopharmaceutical publishes news
Free account required • Unsubscribe anytime